Literature DB >> 18614970

[Metalloproteinases. Structure and function].

Dominik Lipka1, Janusz Boratyński.   

Abstract

Matrix metalloproteinases (MMPs) belong to a large family of multidomain zinc endopeptidases. They are one of the most important proteolitic enzymes which digest components of the extracellular matrix and abundant macromolecules on cell surface and take part in many physiological processes, such as apoptosis or angiogenesis. MMPs are also engaged in the pathogenesis of many diseases such as arthritis and cancer. The development of effective inhibitors and discovery of their mechanisms of action can have significant influence on therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614970

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  13 in total

1.  Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population.

Authors:  Katarzyna Białkowska; Wojciech Marciniak; Magdalena Muszyńska; Piotr Baszuk; Satish Gupta; Katarzyna Jaworska-Bieniek; Grzegorz Sukiennicki; Katarzyna Durda; Tomasz Gromowski; Marcin Lener; Karolina Prajzendanc; Alicja Łukomska; Cezary Cybulski; Tomasz Huzarski; Jacek Gronwald; Tadeusz Dębniak; Jan Lubiński; Anna Jakubowska
Journal:  Hered Cancer Clin Pract       Date:  2020-07-31       Impact factor: 2.857

2.  Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients.

Authors:  Magdalena Drzewiecka-Jędrzejczyk; Rafał Wlazeł; Monika Terlecka; Sławomir Jabłoński
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  Analysis of skin patch test results and metalloproteinase-2 levels in a patient with contact dermatitis.

Authors:  Milena Wojciechowska; Rafał Czajkowski; Bogna Kowaliszyn; Magdalena Żbikowska-Gotz; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2015-06-10       Impact factor: 1.837

4.  Activity of Proteolytic Enzymes and Level of Cystatin C in the Peripartum Period.

Authors:  Anna Cyganek; Aleksandra Wyczalkowska-Tomasik; Patrycja Jarmuzek; Barbara Grzechocinska; Zoulikha Jabiry-Zieniewicz; Leszek Paczek; Miroslaw Wielgos
Journal:  Biomed Res Int       Date:  2016-01-20       Impact factor: 3.411

5.  Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP-2 and TIMP-2 in patients.

Authors:  Edyta Katarzyna Głażewska; Marek Niczyporuk; Sławomir Ławicki; Maciej Szmitkowski; Monika Zajkowska; Grażyna Ewa Będkowska; Andrzej Przylipiak
Journal:  Ther Clin Risk Manag       Date:  2016-10-21       Impact factor: 2.423

6.  Relationship between Serum Levels of Metalloproteinase-8 and Tissue Inhibitor of Metalloproteinases-1 and Exercise Test Results in Postmenopausal Women.

Authors:  J Mieczkowska; E Rutkowska; J Mosiewicz; B Mosiewicz
Journal:  Dis Markers       Date:  2016-12-26       Impact factor: 3.434

7.  Urinary IL-8 is a marker of early and long-term graft function after renal transplantation.

Authors:  Ewa Kwiatkowska; Leszek Domański; Joanna Bober; Krzysztof Safranow; Jolanta Szymańska-Pasternak; Aneta Sulecka; Andrzej Pawlik; Kazimierz Ciechanowski; Sebastian Kwiatkowski
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

8.  Serum concentrations of metalloproteinase 2, metalloproteinase 9 and granzyme B in contact eczema patients.

Authors:  Milena Wojciechowska; Magdalena Zbikowska-Gotz; Rafał Czajkowski; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2013-04-12       Impact factor: 1.837

9.  Expression and Activity of Metalloproteinases in Depression.

Authors:  Kinga Bobińska; Janusz Szemraj; Piotr Czarny; Piotr Gałecki
Journal:  Med Sci Monit       Date:  2016-04-21

10.  Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study.

Authors:  Wiktor Kuliczkowski; Marta Banaszkiewicz; Andrzej Mysiak; Grzegorz Makaś; Iwona Bil-Lula
Journal:  Cardiol Res Pract       Date:  2019-11-04       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.